Sign in

Trial result ·

Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This first-in-human trial tested CJRB-101 with pembrolizumab in advanced cancers. CJRB-101 is a live bacterial product from the species Leuconostoc mesenteroides. It was combined with pembrolizumab to change the tumor microenvironment. Patients had lung cancer, melanoma, or head and neck cancer. Some had not had immunotherapy, and some were refractory to it. The main aims were dose-limiting toxicities, adverse events, and early activity. The team also used lab models grown from patient tumours.

What they found

In the lab models, CJRB-101 with pembrolizumab had more antitumor effect than pembrolizumab alone. The trial enrolled 42 patients. 36 had metastatic lung cancer. 28 were refractory to immunotherapy. None had a dose-limiting toxicity. The treatment was well tolerated. None had a related adverse event above grade 3. One group had 12 lung cancer patients new to immunotherapy, with PD-L1 above 50. Response was more frequent there than in 22 with refractory lung cancer. Median progression-free survival was 9 months in the first group. It was 1.8 months in the second.

What it means for patients

The authors call the early data encouraging. This was for lung cancer with PD-L1 above 50. These patients had not had immunotherapy.

Why it is not certain yet

This was an early trial of 42 patients. Only 12 patients were in the group with the higher response. The lab work used models, not people.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma.

PubMed · PMID 42140743

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Head and neck cancer publications